pfizer started paxlovid ph 2/3 high risk study july 21. results ann 5 nov. eua submitted 16 nov. fda granted eua 22 dec. moves *slowly*. 1 month since ensovibep results announced. approaching 1 year since ph2/3 trial started. still no eua submission